Relmada Therapeutics reports Q1 2023 net loss of $26.3M; provides REL-1017 trial update

RELMADA THERAPEUTICS, INC.

2023-Q1 EPS reported -$0.88

Net loss of $26.3M ($0.87 per share) vs $39.7M ($1.40) in Q1 2022.
R&D expense fell to $15.9M from $25.0M, driven by completion of RELIANCE I and III studies.
Cash, cash equivalents, and short-term investments of $132.4M as of March 31, 2023.
Enrollment ongoing in Phase 3 Study 302 (REL-1017 for MDD); completion expected H1 2024.
New Phase 3 Study 304 to start mid-2023 with ~300 patients; completion anticipated H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023, was $26.3 million, or $0.87 per basic and diluted share, EPS $0.87 per basic and diluted share.

Period: first quarter ended March 31, 2023
Net income: Net loss for the three months ended March 31, 2023, was $26.3 million, or $0.87 per basic and diluted share
EPS: $0.87 per basic and diluted share
Result: preliminary results

Exact text from the filing

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-038577

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.